<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Elmaghraby R</submitter><funding>National Institutes of Health (NIH) Fragile X Centers</funding><pagination>49</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12486676</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>16(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Fragile X syndrome (FXS) is characterized by cortical hyperexcitability, a core neurophysiological feature that contributes to sensory hypersensitivity, cognitive dysfunction, and other disabling symptoms. This disruption in excitatory-inhibitory balance is a key pharmacological target, yet reliable biomarkers to quantify it noninvasively remain limited. Spectral slope, derived from the aperiodic component of the EEG power spectrum, has emerged as a potential index of cortical excitability. Here, we evaluated spectral slope and theta-alpha peak frequency in individuals with FXS to assess their utility as candidate neurophysiological biomarkers.&lt;h4>Methods&lt;/h4>Five minutes of resting state EEG data were collected from 70 subjects with FXS (mean age 20.5 ± 10 years; 32 fem</pubmed_abstract><journal>Molecular autism</journal><pubmed_title>Divergent aperiodic slope and alpha dynamics expose cortical excitability gradients in fragile X syndrome.</pubmed_title><pmcid>PMC12486676</pmcid><funding_grant_id>U54HD082008 and U54HD104461</funding_grant_id><pubmed_authors>Liu Y</pubmed_authors><pubmed_authors>Erickson CA</pubmed_authors><pubmed_authors>Pedapati EV</pubmed_authors><pubmed_authors>Wu SW</pubmed_authors><pubmed_authors>Nelson MA</pubmed_authors><pubmed_authors>Elmaghraby R</pubmed_authors><pubmed_authors>Westerkamp G</pubmed_authors><pubmed_authors>Smith E</pubmed_authors><pubmed_authors>Larsh T</pubmed_authors><pubmed_authors>Ramesh P</pubmed_authors><pubmed_authors>Gilbert DL</pubmed_authors></additional><is_claimable>false</is_claimable><name>Divergent aperiodic slope and alpha dynamics expose cortical excitability gradients in fragile X syndrome.</name><description>&lt;h4>Background&lt;/h4>Fragile X syndrome (FXS) is characterized by cortical hyperexcitability, a core neurophysiological feature that contributes to sensory hypersensitivity, cognitive dysfunction, and other disabling symptoms. This disruption in excitatory-inhibitory balance is a key pharmacological target, yet reliable biomarkers to quantify it noninvasively remain limited. Spectral slope, derived from the aperiodic component of the EEG power spectrum, has emerged as a potential index of cortical excitability. Here, we evaluated spectral slope and theta-alpha peak frequency in individuals with FXS to assess their utility as candidate neurophysiological biomarkers.&lt;h4>Methods&lt;/h4>Five minutes of resting state EEG data were collected from 70 subjects with FXS (mean age 20.5 ± 10 years; 32 fem</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Oct</publication><modification>2026-06-04T00:34:35.157Z</modification><creation>2026-05-03T03:12:11.958Z</creation></dates><accession>S-EPMC12486676</accession><cross_references><pubmed>41029474</pubmed><doi>10.1186/s13229-025-00682-0</doi></cross_references></HashMap>